Your session is about to expire
← Back to Search
SYMPHONY Trial Summary
This trial is testing a new medication for people with narcolepsy who experience sudden muscle weakness (cataplexy) and excessive daytime sleepiness. The goal is to see if the medication is safe and effective.
- Excessive Daytime Sleepiness
SYMPHONY Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
SYMPHONY Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this trial have an upper age limit?
"This study includes individuals that are aged 15 to 75 years old."
What is the projected sample size for this clinical trial?
"That is accurate. The clinicaltrials.gov website has information indicating that this research is currently looking for 43 different sites to enroll a total of 90 patients."
What is the historical record of AXS-12 in medical research?
"The research and development of AXS-12 (reboxetine) was originally conducted in 2008 at Parc Sanitari Sant Joan de Déu. As of now, there are 18,245 completed studies. Out of the 5 active clinical trials, a large number are based in Williamsburg, Virginia."
Has AXS-12 (reboxetine) been authorized by the FDA?
"There is some evidence that AXS-12 (reboxetine) is effective, and multiple studies have shown that it is safe, so our team at Power gave it a score of 3."
Could I be a part of this research if I wanted to be?
"Eligible patients for this study must have a diagnosis of narcolepsy and be between 15-75 years old. Around 90 patients will be admitted in total."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends